[Diltiazem and modulation of platelet aggregation].
The calcium antagonists including Diltiazem have been proved to inhibit platelet aggregation caused by ADP. In order to demonstrate the anti-aggregant properties of Diltiazem, a study was conducted on the aggregation curves in blood samples from 20 healthy subjects before and after a week's treatment with 240 mg oral Diltiazem per diem. The experiment confirmed the anti-aggregant properties of Diltiazem which is therefore useful in the treatment of cardiovascular disease given its capacity to dilate the coronary arteries and inhibit platelet aggregation.
Colica
G
G
Divisione di Medicina, Ospedale E. Morelli, Reggio Calabria.
Salnitro
D
D
Scopelliti
F
F
Sergi
D
D
Pellegrino
R
R
Zoccali
A
A
Lanucara
P
P
D000244:Adenosine Diphosphate / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D000328:Adult; D004110:Diltiazem / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*
D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D004110:Diltiazem
Diltiazem e modulazione dell'aggregazione piastrinica.